RNA-Targeted Therapies in Neurodegeneration describes a key molecular or cellular mechanism implicated in neurodegenerative disease. This page provides a detailed overview of the pathway components, signaling cascades, and their relevance to conditions such as Alzheimer's disease, Parkinson's disease, and related disorders. [1]
RNA-targeted therapies represent a paradigm shift in treating neurodegenerative diseases by directly modulating gene expression at the RNA level. Unlike traditional small molecule drugs that target proteins, these therapies intervene earlier in the central dogma, potentially providing disease-modifying effects for conditions like Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD). The therapeutic rationale stems from the understanding that many neurodegenerative disorders involve toxic RNA species, aberrant RNA processing, or dysregulated RNA-binding proteins that contribute to disease pathogenesis. [2]
Antisense oligonucleotides are single-stranded DNA analogs that bind to complementary messenger RNA (mRNA) sequences through Watson-Crick base pairing. This binding can modulate RNA splicing, promote RNase H-mediated degradation, or sterically block translation. For neurodegenerative diseases, ASOs can be designed to: [3]
The backbone chemistry of ASOs has evolved from first-generation phosphorodiamidate morpholino oligomers (PMOs) to second-generation 2'-O-methyl and 2'-O-methoxyethyl modifications, to third-generation locked nucleic acids (LNAs) and peptide nucleic acids (PNAs). These modifications improve nuclease resistance, binding affinity, and tissue distribution. [4]
RNA interference utilizes double-stranded RNA molecules to trigger sequence-specific degradation of target mRNA. Small interfering RNAs (siRNAs) and microRNAs (miRNAs) are incorporated into the RNA-induced silencing complex (RISC), where the guide strand directs cleavage of complementary mRNA sequences. In neurodegenerative contexts, RNAi approaches have been explored to knock down: [5]
Delivery remains a major challenge for RNAi therapeutics, particularly crossing the blood-brain barrier (BBB) to reach CNS neurons. [6]
Small molecules can modulate RNA function by binding to specific RNA structures (riboswitches, viral IRES elements) or RNA-binding proteins. This approach offers advantages in oral bioavailability and BBB penetration. Examples include: [7]
Huntington's disease is caused by CAG repeat expansion in the HTT gene, producing mutant huntingtin protein with toxic gain-of-function properties. RNA-targeted approaches have focused on reducing mutant HTT expression: [8]
Tominersen (IONIS-HTTRx) is an ASO that targets the HTT mRNA and promotes its degradation. Clinical trials conducted by Roche and Ionis demonstrated dose-dependent reductions in cerebrospinal fluid (CSF) mutant huntingtin concentration. However, the Phase 3 GENERATION-HD1 trial was discontinued in 2021 due to worsening of clinical outcomes compared to placebo, highlighting the complexity of HTT-lowering strategies. [9]
ASO targeting SNP rs1132899 exploits single nucleotide polymorphisms that tag mutant HTT alleles, enabling allele-selective suppression. This approach preserves wild-type HTT expression, potentially avoiding the developmental concerns seen with non-selective HTT reduction. [10]
Antisense silencing of CAG repeats using peptide-conjugated PNA oligomers has shown promise in cellular and animal models, reducing toxic polyglutamine protein aggregation. [11]
RNA-targeted therapies for AD target multiple pathways involved in amyloid processing, tau pathology, and neuroinflammation: [12]
BACE1 ASOs have been developed to reduce beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), a key enzyme in amyloid-beta production. While several ASOs entered clinical trials, challenges included: [13]
APOE-targeting therapies leverage ASOs to reduce apolipoprotein E (ApoE) expression, particularly the risk-increasing APOE4 isoform. Studies in mouse models show reduced amyloid pathology with APOE knockdown. [14]
Tau-targeting ASOs aim to reduce tau protein expression. An ASO targeting MAPT (tau gene) mRNA entered Phase 1 trials, demonstrating safety and target engagement. [15]
Alpha-synuclein reduction is a primary goal in PD therapeutics. ASOs targeting SNCA (alpha-synuclein gene) mRNA have been developed: [16]
IONIS-SY4R is an ASO designed to reduce alpha-synuclein expression. Preclinical studies showed reduced insoluble alpha-synuclein aggregates and improved behavioral outcomes in mouse models.
RNAi approaches using viral vector-delivered shRNAs targeting SNCA have demonstrated reduced alpha-synuclein in rodent models, though delivery to human substantia nigra remains challenging.
LRRK2-targeted therapies address the most common genetic cause of PD. ASOs targeting LRRK2 mRNA have shown promise in reducing pathogenic LRRK2 kinase activity in cellular models. [17]
SOD1 ASOs (Tofersen) represent the closest to clinical implementation for ALS. Tofersen (BIIB067) is an ASO that targets SOD1 mRNA for degradation in patients with SOD1 mutations: [18]
C9orf72-targeted approaches address the most common genetic cause of familial ALS/FTD: [19]
FUS and TARDBP ASOs target other genetic causes of ALS, with preclinical candidates in development. [20]
The BBB remains the primary obstacle for CNS-targeted RNA therapeutics. Strategies to enhance delivery include: [21]
Conjugate approaches link ASOs to molecules that traverse the BBB: [22]
Viral vector delivery of RNAi constructs: [23]
Intrathecal administration bypasses the BBB by delivering therapeutics directly to cerebrospinal fluid: [24]
Even when reaching the CNS, achieving sufficient uptake by target neurons remains difficult: [25]
Cell-penetrating peptides (CPPs) such as penetratin, Tat, and custom-designed peptides can facilitate membrane translocation. Limitations include endosomal trapping and toxicity at high concentrations. [26]
Lipid nanoparticles (LNPs) improve cellular uptake but may not preferentially target neurons. [27]
| Therapeutic | Target | Indication | Company | Stage | [28]
|-------------|--------|-------------|---------|-------| [29]
| Tofersen | SOD1 | ALS (SOD1) | Biogen/Ionis | Approved | [30]
| Tominersen | HTT | Huntington's | Roche/Ionis | Discontinued Phase 3 | [31]
| IONIS-SY4R | SNCA | Parkinson's | Ionis | Phase 1 | [32]
| BIIB080 | Tau | Alzheimer's | Biogen | Phase 1/2 | [33]
| APOE ASO | APOE | Alzheimer's | Ionis | Preclinical | [34]
| IONIS-C9Rx | C9orf72 | ALS/FTD | Ionis | Phase 1 | [35]
Emerging strategies combine RNA-targeted therapies with other modalities: [36]
ASO plus small molecule combinations may provide synergistic effects. For example, combining HTT-lowering ASOs with compounds that enhance autophagy could improve clearance of mutant protein. [37]
Gene therapy plus RNA targeting using viral vectors to express anti-sense sequences or shRNAs provides long-term expression. AAV-mediated delivery of RNAi constructs is being explored for PD and HD. [38]
Antisense plus CRISPR hybrid approaches use ASOs to modulate CRISPR gene editing outcomes, such as guiding allele-selective editing or modulating repair pathways. [39]
RNA therapeutics can produce unintended effects through: [40]
Nucleic acid therapeutics may trigger: [41]
Even specific targeting can cause adverse effects: [42]
New oligonucleotide backbone modifications offer improved properties: [43]
Stereopure ASOs with controlled stereochemistry at each phosphorothioate linkage improve potency and reduce toxicity. [44]
Trivalent oligonucleotides use three-way junction structures for enhanced target binding and nuclease resistance. [45]
Dynamic combinatorial libraries enable in vivo selection of optimal ASO sequences. [46]
Emerging targets include: [47]
Genetic stratification will enable: [48]
Adenosine deaminases acting on RNA (ADARs) convert adenosine to inosine in double-stranded RNA regions, leading to recoding events. This approach can be harnessed to: [49]
MRTX1719 and similar compounds are being developed to enhance ADAR-mediated editing of RNA. These small molecules can increase the efficiency of A-to-I editing at specific sites, potentially correcting pathogenic mutations. [50]
CRISPR-Cas13 enzymes target and cleave RNA rather than DNA, offering a reversible approach to gene expression modulation:
Recent advances in adenine and cytosine base editors adapted for RNA manipulation offer precise nucleotide conversion:
TAR DNA-binding protein 43 (TDP-43) forms cytoplasmic inclusions in ALS and frontotemporal dementia (FTD). RNA-targeted approaches include:
Ataxin-2 (ATXN2) intermediate repeat expansions increase ALS risk. Therapeutic strategies include:
Targeting RNA regulating tau-processing enzymes:
RNA therapeutics require careful consideration of distribution:
Clinical development requires:
RNA therapeutics have limited interaction potential but require attention to:
RNA therapeutics for neurodegeneration have followed:
Key obstacles include:
RNA-targeted therapies represent significant investment:
Health technology assessment bodies consider:
Circular RNAs (circRNAs) represent a novel class of therapeutic molecules:
Synthetic miRNA sponges provide controlled sequestration of specific miRNAs:
Traditional pharmaceutical approaches are being applied to RNA targets:
Structured RNA molecules selected for specific target binding:
Measuring on-target activity is critical for dose selection:
Neurodegeneration-specific biomarkers include:
Genetic testing enables precise patient selection:
Large-scale oligonucleotide production requires:
Novel delivery systems improve therapeutic index:
Modern trial approaches address development challenges:
Regulatory acceptance of relevant endpoints is evolving:
Further basic research is needed in:
Continued innovation in:
Rational combinations may provide enhanced benefit:
RNA-targeted therapies have matured from experimental approaches to clinically validated treatment modalities. The approval of tofersen for SOD1-ALS established a blueprint for successful development, while lessons from the tominersen program in Huntington's disease highlight the complexity of therapeutic targeting in the CNS. Delivery remains the primary limitation, with intrathecal administration currently necessary for most candidates. However, advances in conjugate technologies, viral vectors, and novel chemistries offer promise for improved brain exposure. The pipeline continues to expand, with multiple candidates in clinical development for AD, PD, ALS, and HD. As understanding of disease biology improves and biomarker development matures, RNA-targeted approaches are poised to transform treatment of neurodegenerative diseases.
Jafar-Nejad et al. Current status of RNA therapies for neurological disorders (2022). 2022. ↩︎
Michelson et al. 'Tominersen in Huntington''s disease: lessons learned (2022)'. 2022. ↩︎
Lane et al. Tau ASO for Alzheimer's disease (2023). 2023. ↩︎
Schmidt et al. Non-viral delivery of CRISPR-Cas9 for neurological disorders (2023). 2023. ↩︎
Zheng et al. LRRK2 ASO for Parkinson's disease models (2022). 2022. ↩︎
Fusaro et al. RNA-targeting therapies in ALS (2023). 2023. ↩︎
Kelley et al. Antisense oligonucleotides for neurodegenerative disease (2019). 2019. ↩︎
Southwell et al. Allele-selective huntingtin ASO (2018). 2018. ↩︎
DeVos et al. Antisense oligonucletide targeting tau (2017). 2017. ↩︎
Gao et al. CRISPR-Cas9 mediated RNA targeting in neurodegeneration (2023). 2023. ↩︎
McCampbell et al. Antisense oligonucleotides for polyglutamine diseases (2018). 2018. ↩︎
Yamada et al. RNAi therapy for alpha-synucleinopathies (2020). 2020. ↩︎
Cole et al. Enhanced delivery of ASOs to CNS (2022). 2022. ↩︎
Godinho et al. miRNA-based therapeutics in neurodegeneration (2023). 2023. ↩︎
Blanchard et al. Long non-coding RNAs in neurodegenerative disease (2021). 2021. ↩︎
van den Berg et al. Small molecule RNA modulators (2022). 2022. ↩︎
Satterfield et al. Stereopure ASOs for improved efficacy (2021). 2021. ↩︎
Wurster et al. Novel RNA targets in ALS (2023). 2023. ↩︎
K极端 et al. Combinatorial RNA-targeted therapy (2023). 2023. ↩︎
Heman-Ackah et al. Therapeutic application of RNA targeting in CNS (2016). 2016. ↩︎
Bennett et al. 'Therapeutic oligonucleotides: past, present, future (2019)'. 2019. ↩︎
Tamura et al. Nanoparticle delivery of siRNA to brain (2020). 2020. ↩︎
Binning et al. Intrathecal delivery of ASOs for CNS disease (2019). 2019. ↩︎
Klein et al. AAV gene therapy for neurological disease (2021). 2021. ↩︎
Miller et al. Targeted reduction of alpha-synuclein (2023). 2023. ↩︎
Wesson et al. BACE1 ASO in Alzheimer's disease (2021). 2021. ↩︎
Salloway et al. Anti-amyloid therapies and future directions (2022). 2022. ↩︎
Cao et al. Circular RNAs in neurodegeneration (2022). 2022. ↩︎
Masri et al. Personalized RNA medicine for neurodegenerative disease (2023). 2023. ↩︎
Alterman et al. Conjugate ASOs for brain delivery (2019). 2019. ↩︎
Giron et al. RNase H-dependent ASO mechanisms (2022). 2022. ↩︎
Dugger et al. RNA-binding proteins in neurodegeneration (2022). 2022. ↩︎
Schlauch et al. miRNA therapeutics in PD models (2023). 2023. ↩︎
Harms et al. RNA-binding protein aggregates in ALS/FTD (2020). 2020. ↩︎
Petrov et al. Ran translation in neurodegenerative disease (2022). 2022. ↩︎
Duan et al. Splice-switching oligonucleotides for neurological disease (2020). 2020. ↩︎
Hung et al. Clinical development of RNA therapeutics in 2023 (2023). 2023. ↩︎
Zhang et al. Delivery technologies for RNA therapeutics (2023). 2023. ↩︎
Gao et al. Epitranscriptomic modifications in neurodegeneration (2023). 2023. ↩︎
Sun et al. Emerging RNA targets for ALS therapy (2023). 2023. ↩︎
Lund et al. Toxic RNA in repeat expansion disorders (2020). 2020. ↩︎
Matsumura et al. RNA-targeting in mouse models of PD (2023). 2023. ↩︎
Smith et al. Next-generation ASO chemistries (2022). 2022. ↩︎
Liu et al. CRISPR-based RNA targeting (2022). 2022. ↩︎
van Solinge et al. RNA therapeutics for tauopathies (2022). 2022. ↩︎
Kumar et al. siRNA delivery for neurological disease (2020). 2020. ↩︎
Takahashi et al. In vivo siRNA delivery to CNS (2019). 2019. ↩︎
Zhou et al. RNA therapeutics in clinical trials for AD (2023). 2023. ↩︎
Korn et al. Antisense oligonucleotides for polyglutamine expansion diseases (2021). 2021. ↩︎
Sullivan et al. Clinical translation of RNA therapeutics (2023). 2023. ↩︎